Blood-brain barrier dysfunction in immuno-mediated neurological diseases

The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, incl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunological medicine 2018-07, Vol.41 (3), p.120-128
Hauptverfasser: Shimizu, Fumitaka, Nishihara, Hideaki, Kanda, Takashi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 128
container_issue 3
container_start_page 120
container_title Immunological medicine
container_volume 41
creator Shimizu, Fumitaka
Nishihara, Hideaki
Kanda, Takashi
description The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.
doi_str_mv 10.1080/25785826.2018.1531190
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_25785826_2018_1531190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2202198151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMottT-BGWPXrZOkmY3ualFrVDwoueQZBOJZDc12UX6793SKp48zTDz3jzmQ-gSwwIDhxvCas44qRYEMF9gRjEWcIKm-3m5X5z-6SdonvMHABBYcsHEOZpQEJSTmk7R-j7E2JQ6Kd8VWqXkbSqaXXZDZ3ofu2Ic-7Yduli2tvGqt03R2SHFEN-9UaFofLYq23yBzpwK2c6PdYbeHh9eV-ty8_L0vLrblGaJOZQUAFeWmorXGjQTmNZUKKq00qIm2ljOaqodrpYG20aBoa5iTmEuBGFgKZ2h68PdbYqfg829bH02NgTV2ThkSQgQLDhmeJSyg9SkmHOyTm6Tb1XaSQxyz1H-cJR7jvLIcfRdHSMGPT796_qhNgpuDwLfuZha9RVTaGSvdiEml1RnfJb0_4xvh8OBRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2202198151</pqid></control><display><type>article</type><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><source>Taylor &amp; Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</creator><creatorcontrib>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</creatorcontrib><description>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</description><identifier>ISSN: 2578-5826</identifier><identifier>EISSN: 2578-5826</identifier><identifier>DOI: 10.1080/25785826.2018.1531190</identifier><identifier>PMID: 30938273</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Blood-brain barrier ; endothelial cell autoantibodies ; galectin-3 antibodies ; GRP78 autoantibodies ; immuno-mediated neurological diseases</subject><ispartof>Immunological medicine, 2018-07, Vol.41 (3), p.120-128</ispartof><rights>2018 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group on behalf of the Japanese Society of Clinical Immunology. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</citedby><cites>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/25785826.2018.1531190$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/25785826.2018.1531190$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,27481,27903,27904,59120,59121</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30938273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Nishihara, Hideaki</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><title>Immunological medicine</title><addtitle>Immunol Med</addtitle><description>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</description><subject>Blood-brain barrier</subject><subject>endothelial cell autoantibodies</subject><subject>galectin-3 antibodies</subject><subject>GRP78 autoantibodies</subject><subject>immuno-mediated neurological diseases</subject><issn>2578-5826</issn><issn>2578-5826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kEFLAzEQhYMottT-BGWPXrZOkmY3ualFrVDwoueQZBOJZDc12UX6793SKp48zTDz3jzmQ-gSwwIDhxvCas44qRYEMF9gRjEWcIKm-3m5X5z-6SdonvMHABBYcsHEOZpQEJSTmk7R-j7E2JQ6Kd8VWqXkbSqaXXZDZ3ofu2Ic-7Yduli2tvGqt03R2SHFEN-9UaFofLYq23yBzpwK2c6PdYbeHh9eV-ty8_L0vLrblGaJOZQUAFeWmorXGjQTmNZUKKq00qIm2ljOaqodrpYG20aBoa5iTmEuBGFgKZ2h68PdbYqfg829bH02NgTV2ThkSQgQLDhmeJSyg9SkmHOyTm6Tb1XaSQxyz1H-cJR7jvLIcfRdHSMGPT796_qhNgpuDwLfuZha9RVTaGSvdiEml1RnfJb0_4xvh8OBRg</recordid><startdate>20180703</startdate><enddate>20180703</enddate><creator>Shimizu, Fumitaka</creator><creator>Nishihara, Hideaki</creator><creator>Kanda, Takashi</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180703</creationdate><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><author>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood-brain barrier</topic><topic>endothelial cell autoantibodies</topic><topic>galectin-3 antibodies</topic><topic>GRP78 autoantibodies</topic><topic>immuno-mediated neurological diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Nishihara, Hideaki</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimizu, Fumitaka</au><au>Nishihara, Hideaki</au><au>Kanda, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</atitle><jtitle>Immunological medicine</jtitle><addtitle>Immunol Med</addtitle><date>2018-07-03</date><risdate>2018</risdate><volume>41</volume><issue>3</issue><spage>120</spage><epage>128</epage><pages>120-128</pages><issn>2578-5826</issn><eissn>2578-5826</eissn><abstract>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>30938273</pmid><doi>10.1080/25785826.2018.1531190</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2578-5826
ispartof Immunological medicine, 2018-07, Vol.41 (3), p.120-128
issn 2578-5826
2578-5826
language eng
recordid cdi_crossref_primary_10_1080_25785826_2018_1531190
source Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Blood-brain barrier
endothelial cell autoantibodies
galectin-3 antibodies
GRP78 autoantibodies
immuno-mediated neurological diseases
title Blood-brain barrier dysfunction in immuno-mediated neurological diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A44%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood-brain%20barrier%20dysfunction%20in%20immuno-mediated%20neurological%20diseases&rft.jtitle=Immunological%20medicine&rft.au=Shimizu,%20Fumitaka&rft.date=2018-07-03&rft.volume=41&rft.issue=3&rft.spage=120&rft.epage=128&rft.pages=120-128&rft.issn=2578-5826&rft.eissn=2578-5826&rft_id=info:doi/10.1080/25785826.2018.1531190&rft_dat=%3Cproquest_cross%3E2202198151%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2202198151&rft_id=info:pmid/30938273&rfr_iscdi=true